Table 1 Summary of average number of mutations.

From: In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells

 

WGS

WES

DOX (n = 3)

GEM (n = 3)

PTX (n = 4)

TPT (n = 3)

TPT (n = 3)

DOX (n = 3)

ETP (n = 3)

GEM (n = 3)

PTX (n = 3)

Indels

 Disruptive inframe ins

0.00

0.00

0.00

0.00

1.00

1.00

0.00

0.00

0.00

 Frameshift

0.00

1.00

1.33

2.33

0.00

1.00

1.00

1.00

1.00

 Frameshift plus stop-gained

0.00

0.00

0.00

0.33

0.00

0.00

1.00

0.00

0.00

 Inframe insertion

0.00

0.00

1.00

0.33

0.00

0.00

1.00

0.00

0.00

 Intergenic

27.67

43.00

26.75

24.67

47.67

2.00

3.50

1.00

1.00

 Intragenic

10.00

5.67

9.00

9.00

14.33

1.00

2.00

1.00

1.00

 Intron

12.00

20.33

16.25

15.67

32.33

1.00

1.00

4.00

1.50

 Splice region plus intron

0.00

0.00

0.00

103.3

0.00

0.00

0.00

1.00

0.00

SNVs

 Disruptive inframe del

0.00

1.00

1.00

0.67

0.00

1.00

0.00

1.00

1.33

 Frameshift

1.00

2.00

1.00

22.33

2.00

3.00

1.67

1.00

3.00

 Inframe deletion

0.00

0.00

1.00

0.00

0.00

0.00

2.00

0.00

0.00

 Intergenic

898.33

1303.3

1416.6

258.67

2635.7

25.00

19.00

17.00

21.33

 Intragenic

272.00

403.33

389.25

77.67

834.67

15.33

12.33

10.33

11.33

 Intron

448.67

701.33

764.00

128.3

1358.33

28.00

27.00

33.00

22.67

 Missense

16.00

14.00

12.75

7.00

34.33

15.00

19.67

21.67

15.67

 Others

1.00

1.00

0.00

0.00

1.33

1.00

1.00

1.50

1.00

 Splice region plus intron

1.00

1.67

2.00

30.00

3.33

1.67

1.50

1.00

1.33

 Start lost

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1.00

1.00

 Stop gained

0.00

2.50

1.00

0.00

1.67

1.50

2.00

2.67

0.00

 Stop lost

0.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

 Synonymous

3.00

7.33

4.00

6.33

7.67

6.67

5.33

7.67

5.33

  1. Number of selections performed with the drug is given by n. SNVs and Indels were grouped according to snpEff sequence ontology annotations (“Methods”, Table S9), and detailed counts per clone can be found in Table S4.